Scholarlink

<p>A subset of patients still develops hepatocellular carcinoma (HCC) even after eradication of the hepatitis-C virus (HCV) by anti-HCV treatment. We conducted a genome-wide association study (GWAS) to identify host genetic factors associated with HCC development following HCV eradication in Japan. In this GWAS (<i>n</i> = 517), the discovery cohort included 118 patients without HCC and 67 who developed HCC following HCV eradication with interferon-based therapy. A genome-wide scan for HCC-associated variants was conducted. An independent cohort of 274 patients without HCC and 58 patients with post-eradication HCC was used for replication. The effects of candidate gene variants were assessed clinically and through in vitro cellular assays. The GWAS identified significant variants associated with HCC development following HCV eradication, including rs4778350, located near the long non-coding RNA Prader-Willi non-protein coding RNA 4 (PWRN4) on chromosome 15. In the combined analysis, rs4778350 remained significantly associated with HCC, showing a high odds ratio of 5.86 (95% CI, 3.63–9.44). The frequency of the A allele in rs4778350 differs across ethnic populations. Multivariate analysis revealed that female sex, high platelet count, and higher serum albumin levels were associated with reduced HCC risk, while fibrosis stage F4 and the AA genotype of rs4778350 were linked to increased risk. The AA genotype of rs4778350 enhanced PWRN4 expression, promoting cell proliferation, migration, and invasion. These findings suggest a role for PWRN4 in hepatocarcinogenesis through its association with rs4778350 in patients achieving HCV eradication.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Long non-coding RNA PWRN4 associated with post-SVR hepatocellular carcinoma: a genome-wide association study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月24日

查看全文
  • Goki Suda,
  • Masaya Sugiyama,
  • Hayato Hikita,
  • Akira Nishio,
  • Tomohide Tatsumi,
  • Tetsuo Takehara,
  • Miyako Murakawa,
  • Mina Nakagawa,
  • Yasuhiro Asahina,
  • Masashi Mizokami,
  • Tatsuhiko Kakisaka,
  • Yuzuru Sakamoto,
  • Akinobu Taketomi,
  • Koji Miyanishi,
  • Yoshiyuki Ueno,
  • Hiroaki Haga,
  • Shinya Maekawa,
  • Nobuyuki Enomoto,
  • Masayuki Kurosaki,
  • Motoyuki Kohjima,
  • Makoto Nakamuta,
  • Yasuhito Tanaka,
  • Yoshiya Yamamoto,
  • Masaru Baba,
  • Hisatoshi Hanamatsu,
  • Jun-Ichi Furukawa,
  • Masatsugu Ohara,
  • Takashi Kitagataya,
  • Naoki Kawagishi,
  • Masato Nakai,
  • Takuya Sho,
  • Koji Ogawa,
  • Naoya Sakamoto

摘要

A subset of patients still develops hepatocellular carcinoma (HCC) even after eradication of the hepatitis-C virus (HCV) by anti-HCV treatment. We conducted a genome-wide association study (GWAS) to identify host genetic factors associated with HCC development following HCV eradication in Japan. In this GWAS (n = 517), the discovery cohort included 118 patients without HCC and 67 who developed HCC following HCV eradication with interferon-based therapy. A genome-wide scan for HCC-associated variants was conducted. An independent cohort of 274 patients without HCC and 58 patients with post-eradication HCC was used for replication. The effects of candidate gene variants were assessed clinically and through in vitro cellular assays. The GWAS identified significant variants associated with HCC development following HCV eradication, including rs4778350, located near the long non-coding RNA Prader-Willi non-protein coding RNA 4 (PWRN4) on chromosome 15. In the combined analysis, rs4778350 remained significantly associated with HCC, showing a high odds ratio of 5.86 (95% CI, 3.63–9.44). The frequency of the A allele in rs4778350 differs across ethnic populations. Multivariate analysis revealed that female sex, high platelet count, and higher serum albumin levels were associated with reduced HCC risk, while fibrosis stage F4 and the AA genotype of rs4778350 were linked to increased risk. The AA genotype of rs4778350 enhanced PWRN4 expression, promoting cell proliferation, migration, and invasion. These findings suggest a role for PWRN4 in hepatocarcinogenesis through its association with rs4778350 in patients achieving HCV eradication.